Pembrolizumab Versus Placebo as second-line therapy in patients From Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial
We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC).METHODSIn a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxalipla...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 出版: |
American Society of Clinical Oncology
2023
|
| 主题: | |
| 在线阅读: | http://eprints.um.edu.my/38540/ |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|